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Summary
Raf kinase inhibitor protein (RKIP) is a modulator of
cell signaling that functions as an endogenous inhibi-
tor of multiple kinases. We demonstrate here a posi-
tive role for RKIP in the regulation of cell locomotion.
We discovered that RKIP is the relevant cellular target
of locostatin, a cell migration inhibitor. Locostatin ab-
rogates RKIP’s ability to bind and inhibit Raf-1 kinase,
and it acts by disrupting a protein-protein interaction,
an uncommon mode of action for a small molecule.
Small interfering RNA-mediated silencing of RKIP ex-
pression also reduces cell migration rate. Overex-
pression of RKIP converts epithelial cells to a highly
migratory fibroblast-like phenotype, with dramatic re-
duction in the sensitivity of cells to locostatin. RKIP
is therefore the compound’s valid target and a key
regulator of cell motility.
Introduction
We previously described the biological activity of the
oxazolidinone derivative UIC-1005 [1]. We now rename
this compound locostatin, after its ability to inhibit cell
locomotion in multiple systems, and have identified its
cellular protein targets, which we present here. Our in-
terest in locostatin’s mode of action arose from discov-
ery of its inhibitory activity in a high-throughput assay
for compounds that affect cell migration during wound
closure in Madin-Darby canine kidney (MDCK) epithe-
lial cell monolayers. This screen was performed as part
of our effort to apply a chemical approach to under-
standing the pathways and machinery of cell motility,
processes for which small-molecule inhibitors are pres-
ently limited, with the goal of discovering new chemical
probes and possibly new proteins involved in cell mi-
gration (for a review, see [2]). Moreover, small mole-
cules that modulate cell migration could be of thera-
peutic value: for instance, antimigratory compounds
could be exploited as anticancer agents, since both tu-
mor angiogenesis and metastasis depend on cell mi-
gration, while promigratory compounds could be used
to improve wound healing or may have applications in
tissue engineering. In this report, we show that the bio-
logically relevant target of locostatin is Raf kinase in-
hibitor protein (RKIP), a nonenzymatic regulatory pro-*Correspondence: fenteany@uic.edutein whose ability to interact with Raf kinase is disrupted
by locostatin.
RKIP is a widely expressed modulator of the Raf ki-
nase cascade and other signaling pathways (for re-
views, see [3–5]). RKIP associates with and inhibits the
kinase activity of Raf-1 kinase [6, 7]. Phosphorylation
of RKIP by protein kinase C (PKC) switches RKIP from
Raf-1 to G protein receptor coupled kinase 2 (GRK2) [8,
9]. RKIP has recently been found to interact with and
antagonize the kinase activity of B-Raf as well [10], al-
though Raf-1 activation in vivo may be more under the
control of RKIP than B-Raf activation [11]. In addition,
RKIP can inhibit activation of the transcriptional regula-
tor nuclear factor κB (NFκB) by interacting with and in-
hibiting the activities of kinases involved in NFκB acti-
vation [12]. RKIP was originally isolated on the basis of
its ability to bind phosphatidylethanolamine [13]. It is
therefore also known as phosphatidylethanolamine
binding protein (PEBP), and it can interact with other
ligands as well, although the functional significance of
these interactions is unclear (for reviews, see [3–5]).
RKIP is also the precursor of hippocampal cholinergic
neurostimulating peptide (for a review, see [14]).
Roles for RKIP in diverse biological processes, in-
cluding nervous and cardiac functions, membrane bio-
genesis, and spermatogenesis, have been suggested
(for reviews, see [3–5]). Furthermore, RKIP may play a
negative role in prostate cancer metastasis [15]. In con-
trast, using a chemical approach to the discovery of
biological function, we have discovered that RKIP is
also involved in the positive regulation of epithelial
cell migration.
Results and Discussion
Identification of Locostatin Binding Proteins
Locostatin (compound 1 in Figure 1A) strongly inhibits
membrane protrusion and cell sheet migration, without
affecting gross actin cytoskeletal structure in cells or
salt-induced polymerization of pyrene-actin in vitro ([1]
and data not shown). The compound also inhibits scat-
ter of MDCK cells, induced by hepatocyte growth fac-
tor/scatter factor (HGF/SF), and migration of B16-BL6
murine melanoma cells, a highly invasive and meta-
static cancer cell line, with comparable IC50 values (Ta-
ble S1; see the Supplemental Data available with this
article online). In contrast, locostatin has comparatively
little subtoxic antimigratory effect on the less aggres-
sive A549 human lung adenocarcinoma and MCF7 hu-
man breast adenocarcinoma cells (Table S1).
Since structure-activity relationships strongly sug-
gested that the mechanism of action of locostatin in-
volves covalent modification of a target molecule(s) (Ta-
ble 1 and [1]), we decided to prepare a radioactively
labeled version of the compound, [3H]locostatin (1* in
Figure 1B), to enable the detection and purification of
the locostatin binding proteins. We found that [3H]lo-
costatin specifically and covalently modifies only four
proteins in cytosolic MDCK cell extracts, with no de-
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982Figure 1. Putative Mode of Action of Lo-
costatin and Synthesis of [3H]Locostatin
(A) A nucleophilic residue (Nu:) on the target
protein reacts with the electrophilic carbon
of the Michael acceptor function of 1, as in-
dicated by the arrowhead, forming a cova-
lent complex whereby the protein’s activity
is inhibited. Putative hydrophobic binding
pockets are also shown. This model is sup-
ported by the structure-activity relationship
data in Table 1 and the results showing that
the interaction of compound with protein
survives denaturation with SDS in Figure 2.
(B) Scheme for synthesis of 1* by N-acyla-
tion of the starting oxazolidinone 4 with the
mixed anhydride 3 to form 5, reduction of the
acetylene group of 5 with tritium gas to gen-
erate 6*, and isomerization of the resulting
crotonyl group to yield 1*.tectable binding activity in either nuclear or membrane
fractions, as detected by fluorograms of sodium do-
decyl sulfate (SDS)-polyacrylamide gels of [3H]loco-
statin-treated samples (Figure 2 and data not shown).
Modification of each protein by [3H]locostatin could be
competed away by coincubation with 50-fold molar ex-
cess of unlabeled locostatin over [3H]locostatin, and we
detected no other saturable and specific [3H]locostatin
binding proteins in MDCK cell extracts. The compound
also labels these proteins when live cells are treated
before lysis, showing that locostatin is cell permeant
and can react with the same targets in vivo (data not
shown). The compound’s effects on cells are reversible,
however, most likely as a result of new target biosyn-
thesis following wash out [1]. The approximate molecu-
lar weights of these locostatin binding proteins are 21,
30, 55, and 80 kDa. On the basis of the association of
each protein with [3H]locostatin, we purified all four of
these locostatin binding proteins from MDCK cell ly-
sates. We determined the identity of these proteins by
microcapillary HPLC-linear ion trap tandem mass spec-
trometry (MS) as: (1) the signaling modulator RKIP (w21
kDa); (2) the mechanistically novel glutathione S-trans-
ferase (GST) omega 1-1, or GSTO1-1 (w30 kDa); (3) al-
dehyde dehydrogenase 1A1, or ALDH1A1 (w55 kDa);
and (4) prolyl oligopeptidase (POP), also known as pro-
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wyl endopeptidase (w80 kDa). In addition to isolation
nd identification of the proteins from MDCK cell ly-
ates, we purified ALDH1A1 from A549 cells and bovine
iver. We also expressed the cloned recombinant genes
or RKIP, GSTO1-1, and POP.
ocostatin Reveals the Role of RKIP
n Cell Migration
he reaction of [3H]locostatin with RKIP is saturable
nd specific, since it is competed away with a 50-fold
olar excess of unlabeled compound added simulta-
eously with [3H]locostatin in both samples for MDCK
ell extracts (Figure 2A) and bacterially expressed re-
ombinant rat RKIP (Figure 2B). We calculated the sec-
nd-order rate constant for association of locostatin
ith RKIP as 13.09 M−1 s−1 (Table S2). Furthermore,
inding competition experiments performed with a
eries of unlabeled locostatin analogs show a correla-
ion between the antimigratory activity of the analogs
nd their ability to compete with [3H]locostatin for bind-
ng to RKIP (Figure 2B and Table 1), implying that RKIP
ay be a physiologically relevant target of locostatin.
n addition, the fact that some of the cytotoxic com-
ounds lacking any subtoxic effect do not compete
ell with [3H]locostatin for binding to RKIP shows that
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983Table 1. Structure-Activity Relationships
Compound R1 R2 R3 R4 R5 IC50/Activity
1 (locostatin) H Bn H H 17.9 Ma (96%, 50 M)b
7 H Bn H H no activity
8 H Bn H H slight activity at 20 M only (49%)b; toxic
at R50 M
9 H i-Pr H H 39.5 Ma (78%, 100 M)b
10 H Bn H H toxic at R100 Mc
11 H Me H Ph 22.6 Ma (60%, 50 M)b
12 H Ph H H 23.7 Ma (83%, 50 M)b
13 H Bn H H slight activity at 5 M only (36%)b; toxic at
R10 M
14 Bn H H H toxic at R100 Mc
15 H Bn H H toxic at R50 Mc
16 H Bn H H slight activity at 500 nM only (24%)b; toxic
at R1 M
17 H Bn H H 81.5 Ma (31%, 1 mM)b
18 H Bn H H slight activity at 100 M only (42%)b; toxic
at R200 M
d
thiazolidinethione analog
a All IC50 values were calculated for inhibition of wound closure at the indicated times postwounding with normalization to parallel controls
by using R5 different subtoxic concentrations in concentration-response experiments. Each concentration for each cell type and assay
involved at least three separate experiments and was considered a bioactive concentration if there was statistically significant inhibition with
p < 0.05 by an unpaired two-tailed Student’s t test. All experiments were performed in serum-containing medium, unless otherwise noted.
Our previously published value for the IC50 of locostatin based on percent inhibition of wound closure at 12 hr postwounding was 14 M [1].
b Values in parentheses represent the percent inhibition of wound closure at 24 hr postwounding normalized to parallel controls for the highest
subtoxic concentrations, as indicated. The higher the percentage, the more inhibitory the compound is at 24 hr relative to the parallel controls.
c Compounds labeled simply as toxic were cytotoxic starting at the indicated concentration but had no subtoxic inhibitory activity at any
lower concentration in wound closure assays. Toxicity was defined on the basis of rounding up of cells and Trypan blue staining. The values
in parentheses represent the minimum lethal concentration for these compounds.
d 18, the thiazolidinethione analog of locostatin, has a less electrophilic α,β-unsaturated N-crotonyl group than locostatin and so should be
less reactive with any nucleophile.modification of RKIP and cytotoxicity are not strictly
linked.
Locostatin hinders the ability of RKIP to inhibit Raf-1
kinase in vitro, thereby restoring the kinase activity of
Raf-1 (Figure 3A) and making it, to our knowledge, thefirst inhibitor of RKIP discovered. Locostatin has no di-
rect effect on the activity of Raf-1 kinase alone in con-
trol experiments; however, it is weakly inhibitory of sub-
strate phosphorylation at elevated concentrations of
R1 mM, most likely as a result of nonspecific alkylation
Chemistry & Biology
984Figure 2. RKIP Is a Specific Target of Lo-
costatin
(A and B) Fluorograms of SDS-polyacryl-
amide gels of (A) partially purified MDCK cell
extracts or (B) recombinant rat RKIP treated
with 1 M [3H]locostatin (1*) for 3 hr, with or
without 50 M unlabeled locostatin (1) or un-
labeled analogs 7–18 (structures in Table 1).
The w21 kDa locostatin binding protein was
identified as RKIP by tandem MS following
2D gel electrophoresis of the partially puri-
fied samples from MDCK cell lysates. In (B),
relative bioactivity in the MDCK wound clo-
sure assay for each locostatin analog is
shown above the fluorogram. The com-
pounds labeled “Tox” are cytotoxic starting
at different concentrations (indicated in Ta-
ble 1), but display little or no subtoxic effect
on cell migration and wound closure. Iden-
tical results for [3H]locostatin binding were
obtained when treating live cells with [3H]lo-
costatin before cell lysis, demonstrating that
the compound is membrane permeant and
capable of modifying RKIP in vivo also.at high concentrations. The mode of action of lo-
costatin in the inactivation of RKIP involves disruption
of the interaction between RKIP and Raf-1, with modifi-
cation of RKIP by locostatin abolishing the ability of
RKIP to bind Raf-1 (Figure 3B).
To further validate RKIP as a relevant target, we used
RNAi to silence RKIP expression in MDCK cells (Figure
4A). Cells expressing a small interfering RNA (siRNA)
targeting RKIP migrate more slowly than control cells
(Figure 4B). The effect of RKIP knockdown recapitu-
lates that of locostatin on cell migration. These results
therefore further validate RKIP as the relevant target of
locostatin, and they further implicate RKIP in cell mi-
gration.
We also performed the opposite manipulation, increas-
ing rather than decreasing the levels of RKIP in MDCK
cells, and evaluated the effect of overexpression of
RKIP on the cells and their sensitivity to locostatin. We
found dramatic changes in the morphology and migra-
tion of MDCK cells with RKIP overexpression (Figure 5).
The RKIP-overexpressing cells grow without much cell-
cell contact, like fibroblasts, rather than as islands in
which cells strongly adhere to each other, like normal
MDCK cells. Upon scratch wounding of confluent mono-
layers, normal MDCK cells migrate collectively as a
continuous sheet, never losing their cell-cell contacts in
the manner characteristic of strongly cell-cell adherent
differentiated epithelial cells (Figure 5A and [16, 17]).
In contrast, after wounding of confluent monolayers of
MDCK cells that are overexpressing RKIP, migrating
cells break away from the sheet, crawling as individual
single cells not adhering to one another (Figure 5B),
rather than collectively. This change is reminiscent of
what occurs upon treatment of subconfluent MDCK cell
cultures with HGF/SF, which results in conversion of the
cells to a migratory and dispersing fibroblast-like phe-
notype (for a review, see [18]). It is accompanied by
loss of cell-cell adhesions such as adherens junctions,
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mhich depend on E-cadherin, the primary cell adhesion
olecule in MDCK [19, 20] and other epithelial cells (for
eviews, see [21, 22]). The change in phenotype resem-
les the epithelial-mesenchymal transition (EMT) that
ertain epithelial cells undergo during embryonic de-
elopment and in the progression of many epithelial
ancers, and HGF/SF-treated MDCK cells have been
idely used as a model for EMT (for reviews, see [23,
4]).
Treatment with locostatin appears to cause a mor-
hological change of the RKIP-overexpressing MDCK
ells to a less elongated and more cell-cell adhesive
tate (Figure 5D); however, this is not a complete rever-
ion of cells back to a normal cuboidal epithelial phe-
otype, perhaps because of the relatively short time of
xposure to locostatin, the high level of RKIP expres-
ion under the control of the human cytomegalovirus
CMV) promoter, or the simultaneous inhibition of the
ompound’s other targets. It would have been interest-
ng to grow the RKIP-overexpressing cells in the pres-
nce of locostatin; however, this was not possible since
ocostatin also inhibits cell proliferation [1]. However,
he ability of locostatin to inhibit cell migration and
ound closure is dramatically reduced when RKIP is
verexpressed (Figure 6). There is little effect on the
igration of RKIP-overexpressing cells with treatment
f locostatin at subtoxic concentrations that strongly
nhibit wound closure in control MDCK cells. At higher
oncentrations, locostatin is similarly toxic in both the
KIP-overexpressing MDCK cells and control cells. This
uggests that the toxicity of the compound at higher con-
entrations is mediated by the inhibition of other targets,
hile the subtoxic antimigratory effect is due to the inhibi-
ion of RKIP. In addition, the RKIP-overexpressing cells
end to round up and die with long-term maintenance
f the cultures at confluence, consistent with previous
ork showing that RKIP has proapoptotic activity in hu-
an prostate and breast cancer cells [25]. We found
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985Figure 3. Locostatin Abrogates the Ability of RKIP to Inhibit the
Kinase Activity of Raf-1 In Vitro by Preventing Interaction between
the Two Proteins
(A) Locostatin hinders RKIP’s ability to inhibit Raf-1 in vitro (100
M locostatin; 3 hr of preincubation; control contains an equivalent
volume percent of DMSO carrier solvent alone). Known amounts of
expressed and purified recombinant RKIP (3.8 g, which corre-
sponds to 9 M in the initial sample volume), activated Raf-1 (1 l
dilute purified sample), MEK1 (0.4 g), and kinase-negative ERK2
(1.0 g) were used in an in vitro Raf/MEK/ERK reaction sequence,
as previously described [42], and equivalent amounts of sample
were loaded onto the gel for each lane. The dominant band corre-
sponds to the fraction of the fixed amount of kinase-negative ERK2
in each lane that has been 32P-phosphorylated in the presence or
absence of RKIP and locostatin. See Experimental Procedures for
details. (Locostatin has no direct effect on the kinase activity of
Raf-1 alone, although it weakly inhibits phosphorylation of MEK
at R1 mM.)
(B) Alkylation of RKIP by locostatin prevents RKIP from interacting
with Raf-1. RKIP preincubated with locostatin is not coimmunode-
pleted from solution with an anti-Raf-1 antibody in vitro (100 M
locostatin; 70 nM RKIP; 3 hr of preincubation; 20 l volume in each
case), as detected by Western blot analysis with an anti-RKIP anti-
body, while RKIP preincubated with DMSO alone is pulled out
along with Raf-1 by the anti-Raf-1 antibody. The immunodepleted
fraction is shown in both cases; therefore, the presence of an RKIP
band means that the interaction with Raf-1 was inhibited by lo-
costatin treatment.
The data in both (A) and (B) are representative of three separate ex-
periments.Figure 4. siRNA-Mediated Silencing of RKIP Expression Reduces
the Rate of Migration of Epithelial Cells
(A) Western blot demonstrating knockdown of RKIP in MDCK cells
expressing an siRNA corresponding to nucleotides 285–303 of the
canine RKIP gene. The siRNA is expressed from a stably trans-
fected expression vector described in Experimental Procedures.
The control cells carry the same vector expressing an inert siRNA.
Identical numbers of cells and amounts of total protein were loaded
in both cases, as determined by counting cells with a hemocytome-
ter before cell lysis and then Bradford assays after cell lysis. The
loading control with anti-β-actin antibody is next to an anti-RKIP
antibody probe; results are representative of three independent ex-
periments.
(B) RKIP knockdown cells migrate more slowly than control cells in
the wound closure assay (mean ± standard error of the mean for n
wounds as indicated).that treatment of the RKIP-overexpressing cells with lo-
costatin protects them from death. Collectively, these
data show that RKIP is the biologically relevant target
of locostatin in MDCK cells and that RKIP is a critical
regulator of epithelial cell migration.
Other Targets Not Involved in Cell Motility
We also investigated the effects of locostatin on the
function of the other locostatin binding proteins and
looked at the possible role of these proteins in wound
closure. Locostatin inhibits ALDH1A1 with a second-
order inactivation rate constant of 107.4 M−1s−1 (TableS2). However, when we tested four different available
ALDH inhibitors (disulfiram, citral, p-chloromercuriben-
zoic acid, and cyanamide) for any effects on MDCK
wound closure, we found no subtoxic inhibitory activity.
These inhibitors compete with [3H]locostatin for bind-
ing ALDH1A1 both in vitro and in vivo (the latter by
short-term exposure of cells to [3H]locostatin with or
without high excess concentrations of unlabeled inhibi-
tors, demonstrating that the inhibitors readily enter
cells and bind cellular ALDH1A1). Therefore, inhibition
of ALDH1A1 does not explain the effects of locostatin
on MDCK cell migration, although it could still account
for the toxicity of locostatin at higher concentrations.
In addition, A549 cells, which contain much higher
levels of ALDH1A1, are little affected in wound closure
assays by locostatin at subtoxic concentrations.
Locostatin also inhibits POP with a second-order in-
activation rate constant of 2.08 M−1s−1 (Table S2). How-
ever, treatment of MDCK cells with two available selec-
tive cell-permeant POP inhibitors, Z-Pro-Pro-CHO and
Boc-Glu(NHO-Bz)-Pyr, which are extremely potent (pM
and nM Ki values, respectively, for inhibition of POP),
results in partial inhibition of wound closure only ob-
served at very high concentrations (>200 M), concen-
trations that are not far from where they become mani-
Chemistry & Biology
986Figure 5. Overexpression of RKIP in Epithe-
lial Cells Results in Conversion of Cells to a
Fibroblast-Like Morphology
(A) Control MDCK cells stably transfected
with EGFP alone.
(B) Stably transfected MDCK cells overex-
pressing RKIP-EGFP.
(C) Control stably EGFP-transfected MDCK
cells treated with locostatin.
(D) Stably RKIP-EGFP-transfected MDCK
cells treated with locostatin.
Treatments of confluent cell monolayers be-
gan 30 min before wounding (0.1% DMSO car-
rier solvent or 50 M locostatin), and each
monolayer was similarly scratch wounded and
then imaged 6 hr after wounding. The fluores-
cence images show the high level of expres-
sion of (A and C) EGFP or (B and D) RKIP-
EGFP, driven from the CMV promoter in the
EGFP-C1 mammalian expression vector in
both cases. Images are representative of at
least three separate experiments in each case.
Similar results were obtained following overex-
pression of hemagglutinin-tagged RKIP. Bars,
50 m.festly cytotoxic and thousands of times higher than
their Ki values for inhibition of POP.
GSTO1-1 activity is also inhibited by locostatin,
though extremely slowly, with second-order inactiva-
tion rate constants of 0.108 M−1s−1 in the DHA reduc-
tase assay and 0.063 M−1s−1 in the thiol transferase as-
say (Table S2), two assays of GSTO1-1 activity. However,
again, treatment of MDCK cells with other GST inhibi-
tors does not affect wound closure.
RKIP and POP are both unique proteins, although
they are part of larger protein families: the PEBP and
POP families, respectively. There are a number of ALDH
and GST isoforms with different functions. We have not
detected any other isoforms of either ALDH or GST as
locostatin binding proteins by tandem MS, demonstrat-
ing the high degree of selectivity of locostatin for a sin-
gle isoform of both enzyme classes. Both ALDH1A1
and GSTO1-1 have probable in vivo xenobiotic-metab-
olizing activities, like many of the better-characterized
isoforms of these proteins.
RKIP and Cell Migration
Our results strongly suggest that RKIP is the only pro-
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ctein among the four locostatin binding proteins thatlays a role in epithelial cell sheet migration during
ound closure. Locostatin is the only inhibitor of RKIP
iscovered to date and acts by disrupting RKIP’s ability
o bind and inhibit Raf-1 kinase. It is unclear at this
ime how this inhibition leads to arrest of cell motility.
nhibition of RKIP could result in inappropriate stimula-
ion of Raf-1, leading to activation of the MEK/ERK
athway, which may negatively regulate migration of
DCK cell sheets. We have previously found that the
EK inhibitors PD98059 and U0126 have little or no
ffect on wound closure in MDCK cell monolayers [26],
ut we have not analyzed the opposite manipulation,
here the pathway is overactivated. It seems more
ikely, however, that the major part of RKIP’s role in the
egulation of cell migration results from inhibition of
ther effectors that could be downstream of Raf-1,
part from the MEK/ERK pathway, or else modulation
f the activity of proteins other than Raf-1, such as
RK2 or another RKIP-regulated protein. Locostatin
ay also interfere with RKIP’s ability to bind some
ther ligand, such as phosphatidylethanolamine, which
ould be important for epithelial cell migration.
RKIP is not itself an enzyme, but a nonenzymatic reg-
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987Figure 6. Overexpression of RKIP Dramatically Reduces the Antimi-
gratory Effect of Locostatin and Results in More Rapid Cell Mi-
gration
Cells overexpressing RKIP are no longer significantly inhibited in
wound closure assays by concentrations of locostatin at or below
50 M, and they migrate faster than control cells (mean ± standard
error of the mean for n wounds as indicated). In contrast, locostatin
inhibits wound closure in normal MDCK cells down to 2 M. Above
50 M, locostatin becomes cytotoxic in the RKIP-overexpressing
MDCK cells, as in control cells, suggesting that the toxicity at
higher concentrations is mediated by the inhibition of other targets,
while the antimigratory effect at subtoxic concentrations is medi-
ated by the inhibition of RKIP. In addition, locostatin protects the
RKIP-overexpressing cells from death with long-term culture,
which we have found occurs without locostatin treatment (data
not shown).ulator of multiple kinases that acts through protein-pro-
tein interactions. Alkylation of RKIP by locostatin pre-
vents it from binding Raf kinase either by directly
targeting the protein-protein interaction interface or by
an allosteric mechanism that alters the conformation
of the interface region of RKIP. Although there is great
interest in the development of compounds like lo-
costatin that disrupt protein-protein interactions, par-
ticularly between signaling proteins, this is still a rela-
tively uncommon mode of action for small-molecule
inhibitors, the majority of which target enzyme active
sites (for reviews, see [27–37]). Ser153 of RKIP can be
phosphorylated by PKC, resulting in dissociation from
Raf-1 and association with and inhibition of GRK2 [9].
In experiments testing whether this nucleophilic resi-
due could be modified by locostatin, we found that pre-
incubation of RKIP with locostatin does not affect the
level of phosphorylation of RKIP by PKC (data not
shown). Moreover, mutation of Ser153 to Ala does not
affect the level of alkylation at saturation of RKIP by
[3H]locostatin (data not shown). These results suggest
that locostatin does not modify Ser153. We are now
investigating the detailed molecular mechanism of ac-
tion of locostatin and the role of RKIP in regulating mi-
gration of the epithelial cell sheet during wound closure.
Recently, RKIP expression was found to be higher in
a tumorigenic and metastatic murine fibrosarcoma cell
line than in the weakly tumorigenic and nonmetastatic
parental cell line from which it derives [38]. However, in
contrast, RKIP levels are low in human prostate and
breast cancer cells [15, 25], as well as in human mela-noma cells, where overexpression of RKIP partially in-
hibits B-Raf-mediated, anchorage-independent growth
[10]. Moreover, overexpression of RKIP reduces the in-
vasiveness of human prostate cancer cells in vitro and
appears to suppress metastasis in vivo by decreasing
angiogenesis and vascular invasion [15]. Such activity
appears to be opposite to that in MDCK epithelial cells,
in which RKIP overexpression converts the cells to a
fibroblast-like morphology and promotes migration.
These different results cannot as yet be reconciled.
They may indicate diverse and context-dependent
functions for RKIP in the positive and negative control
of cell motility, leading to the possibility that RKIP could
function in different ways to either promote or suppress
invasion and metastasis, depending on the type of
cancer.
Significance
Using a small-molecule inhibitor, we have discovered
that RKIP is necessary for the collective migration of
epithelial cells. This compound inhibits epithelial cell
migration and prevents RKIP from associating with
and inhibiting Raf-1 kinase by disrupting the protein-
protein interaction between RKIP and Raf-1. Silencing
of RKIP expression by using RNAi also decreases the
rate of cell migration. Overexpression of RKIP causes
transformation of epithelial cells to a fibroblast-like
phenotype, resulting in dispersion and migration of
the cells as individuals. Furthermore, these results
raise the possibility that initiation of collective migra-
tion of an epithelial cell sheet could itself represent a
partial temporary transition to a more mesenchymal
state, with acquisition of a more “invasive” character,
but without loss of cell-cell contacts. To our knowl-
edge, RKIP has not been shown to play a positive role
in cell migration before this study, and, therefore,
these results open up a new avenue for research on
RKIP and cell motility.
Experimental Procedures
Synthesis of [3H]Locostatin and Locostatin Analogs
[3H]Locostatin (1*, 58 Ci mmol−1) was synthesized from the corre-
sponding acetylene 5, which was itself prepared by a previously
described procedure [1], as were the other analogs used in this
study. The structure and purity of all compounds were confirmed
by nuclear magnetic resonance (NMR) and high-resolution mass
spectrometry (HRMS).
Briefly, for synthesis of 5, 2-butynoic acid (2, 70.62 mg, 0.84
mmol), trimethylacetyl chloride (101.2 mg, 0.84 mmol), and triethyl-
amine (96.4 mg, 0.96 mmol) were dissolved in tetrahydrofuran
(THF), cooled to −78°C, and stirred for 1 hr. The temperature was
raised to 0°C, and the solution was stirred for 1 hr. The liquid mix-
ture containing the mixed anhydride 3 was added dropwise to a
solution of (4S)-(-)-benzyl-2-oxazolidinone (4, 100 mg, 0.56 mmol)
and n-butyllithium (1.6 M in hexanes, 0.36 ml, 0.56 mmol) in THF
that had been cooled to −78°C and stirred for 30 min. The reaction
mixture was stirred at −78°C for 1 hr and allowed to warm to room
temperature. The reaction was quenched with a saturated NH4Cl
solution and diluted with ethyl acetate and washed twice with H2O
and once with brine. The organic layer was dried over Na2SO4 and
evaporated under reduced pressure. The product was purified by
flash chromatography with silica gel using ethyl acetate:hexanes
(1:1) as eluent. 5 (102.6 mg, white solid) was obtained, as verified
by NMR. 6* was prepared from 5 by reduction of the acetylene with
tritium gas as follows. 5 (12 mg, 0.05 mmol) was dissolved in ethyl
acetate, and Lindlar catalyst (2 mg) was added. The system was
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The reaction mixture was stirred at room temperature for 5 hr. 6*
was purified with preparative thin layer chromatography (TLC) with
a specific activity of 58 Ci mmol−1. 1* was then prepared from 6*
by isomerization of the crotonyl group. For this, 6* was dissolved
in CCl4, and a small crystal of diphenyl disulfide was added. The
reaction vessel was flushed with argon gas and fitted with a con-
denser, and an argon gas balloon was attached. The reaction mix-
ture was irradiated with a projector lamp (70 volts, 60 watts) for 1.5
hr. The resulting 1* was purified by preparative TLC, and its struc-
ture was established by NMR.
Locostatin (1, prepared by reduction of 5 to 6 with H2 and isomer-
ization to 1, as described above for 1*): white solid; m.p. 83–84°C;
1H NMR (500 MHz, CDCl3): δ 7.34–7.21 (m, 7H, Ph, CH=CH), 4.75–
4.70 (m, 1H, CHN), 4.22–4.16 (m, 2H, CH2O), 3.33 (dd, 1H, J = 3.4,
13.4 Hz, CHHPh), 2.80 (dd, 1H, J = 9.6, 13.4 Hz, CHHPh), 1.99 (dd,
3H, J = 0.9, 6.3 Hz, CH3) ppm; 13C NMR (100 MHz, CDCl3): δ 164.87,
153.36, 146.93, 135.28, 129.37, 128.85, 127.22, 121.75, 66.01, 55.20,
37.79, 18.50 ppm; HRMS (EI) m/z calcd for C14H15NO3 [M]+
245.1052, found 245.1060.
Cell Culture and Cell Migration Assays
MDCK cells were grown to confluence in minimum essential me-
dium (MEM) supplemented with 10% newborn calf serum (NCS)
and then scratch wounded and analyzed as previously described
[1]. Because the RKIP-overexpressing MDCK cells migrated as in-
dividuals following wounding of confluent monolayers, the open
area was determined by tracing the edge of the remaining intact
cell monolayer, as for wounds in normal MDCK cell sheets, but then
subtracting the area occupied by cells migrating into the wound
area as individuals to obtain the correct unoccupied area as a func-
tion of time. Curve fitting and statistical analyses were done by
using GraphPad Prism software.
Isolation of Protein Targets
Confluent MDCK cell monolayers were rinsed with phosphate-buf-
fered saline (PBS) thrice and incubated on ice for 30 min in lysis
buffer consisting of 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1%
Sigma protease inhibitors cocktail solution for mammalian cell and
tissue extracts, 0.5% Triton X-100, and 2 mM dithiothreitol (DTT).
The cells were scraped off the plates and dounce homogenized.
The crude extract was centrifuged at 15,000 × g for 30 min at 4°C,
and then the supernatant was carefully decanted and saved for
binding assays or further purification. Locostatin binding experi-
ments were performed by adding [3H]locostatin to small aliquots
of the extract samples, followed by incubation at 16°C for 3 hr.
Saturability and specificity of the reaction between locostatin and
its binding proteins were determined by adding 50-fold molar ex-
cess of unlabeled locostatin simultaneously with [3H]locostatin in
binding competition experiments. After incubation, the sample was
subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
The gel was stained with Coomassie blue, shaken in Amplify fluo-
rography solution (Amersham) for 30 min, placed on filter paper,
and dried. The dried gel was then exposed to Amersham Hyperfilm
autoradiography film at −80°C, and the film was developed to visu-
alize the proteins radioactively labeled by reaction with [3H]loco-
statin.
[3H]Locostatin binding assay-guided purification of the specific
locostatin binding proteins was accomplished as follows. MDCK
cell extracts in lysis buffer were dialyzed against 20 mM bis-Tris
(pH 6.0), 2 mM DTT overnight and centrifuged at 15,000 × g for 30
min. The supernatant was applied to a HiTrap Q-sepharose column
(Amersham Biosciences), and the flow-through was collected. Pro-
teins were eluted from the column with a linear gradient of NaCl
and set aside. The flow-through was then fractionated by pro-
gressive precipitation as 25%, 40%, 50%, 60%, and 80% ammo-
nium sulfate pellets. Ammonium sulfate precipitates containing
w21, w30, and w55 kDa locostatin binding proteins were resus-
pended in PBS, desalted by centrifugation at 5,000 × g in Amicon
(Millipore) centrifugal filter units with the addition of ultrapure H2O,
subjected to two-dimensional (2D) gel electrophoresis on a flatbed
isoelectric focusing system (Scie-Plas), and stained with Coomas-
sie brilliant blue R-250. In contrast to the other three proteins, the
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c80 kDa locostatin binding protein bound to the Q-sepharose col-
mn; following elution, the w80 kDa locostatin binding fractions
ere pooled, subjected to SDS-PAGE, and stained with Coomassie
rilliant blue R-250. Each relevant protein band or spot was cleanly
esolved on the gels and lined up with [3H]locostatin binding pro-
eins on fluorograms of parallel gels prepared as described above.
ll bands or spots corresponding to [3H]locostatin binding activi-
ies were cut out from the gels.
arget Identification
xcised protein bands were subjected to in gel reduction, carboxy-
midomethylation, and digestion with trypsin. Peptide sequences
ere determined by using a 75 m reverse phase microcolumn
erminating in a custom nanoelectrospray source (New Objective)
irectly coupled to an LTQ linear quadrupole ion trap mass spec-
rometer (Thermo Electron). The instrument was operated in data-
ependent mode, fragmenting (relative collision energy = 30%,
solation width = 2.5 Da, dynamic exclusion on) the four most abun-
ant ions in each survey scan. Preliminary sequencing of peptides
as facilitated by correlation of the National Center for Biotechnol-
gy Information (NCBI) nr database with the algorithm SEQUEST
39], an in-house spectrum review workbench, FuzzyIons, and neu-
al network ScoreFinal. All protein assignments met the following
riteria: (i) a minimum of four unique peptide sequences; (ii) a mini-
um of ten MS/MS-acquired spectra allowing for redundant se-
uences; (iii) a ScoreFinal R 0.83. ScoreFinal is a single Sequest
core that we developed; is implemented in Sequest Browser v.
.2; and is the output, normalized to 1.00, of a neural network (with
ne hidden layer) whose inputs are the five Sequest scores (XCorr,
Cn, Sp, rSp, and Ions), peptide charge state, mass, and database
ize. Evaluation with a reverse NCBI nr database reveals a peptide
alse positive rate of < 0.5% when ScoreFinal > 0.8. Finally, (iv) all
pectra were manually inspected for completeness of ion assign-
ents and intensity-based signatures, e.g., neutral loss(es), proline
ons, etc.
xpression and Purification of Recombinant Genes
e expressed recombinant genes in Escherichia coli (DH5α or
M109 strains) following CaCl2-mediated transformation of the
acteria. Rat RKIP fused to GST in the pGEX-KG vector was ex-
ressed and purified as previously described [6]. His6-tagged
STO1-1 in pQE30 was expressed and purified as previously de-
cribed [40]. His6-tagged POP in pCHH29 was also expressed and
urified as previously described [41]. The Raf-1 kinase assay in-
olved multiple recombinant kinases: Raf-1, a kinase-negative mu-
ant of extracellular signal-regulated kinase 2 (ERK2) and mitogen-
ctivated protein kinase/ERK kinase 1 (MEK1). GST-Raf-1 in pEBG,
ST-MEK1 in pGEX-KG, and GST-ERK2 in pGEX-KG were ex-
ressed and purified as previously described [42]. The GST-Raf-
-containing construct was transfected into COS-7 cells by using
ipofectamine and was activated by treating the cells with 100 nM
horbol 12-myristate 13-acetate for 15 min before cell lysis. GST-
af-1 was purified by using glutathione-agarose beads and was
luted from the beads with 10 mM reduced glutathione. GST was
leaved from all of the recombinant proteins with thrombin.
urification of ALDH1A1
LDH1A1 was purified from MDCK cells, A549 cells, and bovine
iver on the basis of [3H]locostatin binding assays performed with
amples of each fraction. Purification from MDCK cells involved
-sepharose column chromatography (pH 6.0, collection of [3H]lo-
ostatin binding activity in the flow through), ammonium sulfate
recipitation (50%–60% fraction), gel filtration (the ALDH1A1 tetra-
er is w220 kDa), and phenyl hydrophobic column chromatogra-
hy. For purification from A549 cells, the scheme involved Q-seph-
rose column chromatography (pH 8.0, elution at 200–400 mM
aCl), ammonium sulfate precipitation (50%–60% fraction), gel
iltration, and phenyl hydrophobic column chromatography. For pu-
ification from bovine liver, the sequence entailed ammonium sul-
ate precipitation (50%–70% fraction), Q-sepharose column chro-
atography (pH 8.0, elution w200 mM NaCl), hydrophobic column
hromatography, and gel filtration. All steps were done at 4°C.
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989Raf Kinase Enzyme Assay
The assay involves in vitro reconstitution of the Raf/MEK/ERK cas-
cade as previously described [42]. A total of 3.8 g purified recom-
binant RKIP, corresponding to 9 M in the initial sample volume,
was preincubated at 16°C for 3 hr with 100 M locostatin, or an
equivalent volume percent of dimethyl sulfoxide (DMSO) carrier
solvent alone, in 20 l kinase buffer (40 mM Tris-HCl [pH 7.5], 0.1
mM EDTA, 5 mM MgCl2, 2 mM DTT, 20 M ATP). Activated Raf-1
(1 l dilute purified sample) was then added to the solution. After
incubation on ice for 30 min, 0.4 g MEK1 and 10 Ci [32P]γ-ATP
were added, followed by incubation at 37°C for 30 min. MEK1 32P-
phosphorylation is not readily detectable on autroradiograms, so
in a subsequent kinase “signal amplification” step, 1.0 g kinase-
negative ERK2, a substrate of MEK1, was added to the reaction
mixture with incubation for another 30 min at 37°C. The reaction
was stopped by the addition of SDS sample buffer and was then
subjected to SDS-PAGE. After staining with Coomassie blue, the
gel was dried and exposed to autoradiography film for detection of
32P-phosphorylated ERK2.
RKIP-Raf-1 Binding
70 nM RKIP was preincubated with 100 M locostatin or DMSO
carrier solvent alone at 16°C for 3 hr, then mixed with activated
Raf-1 in kinase buffer and incubated on ice for 30 min. A total of 2
g rabbit anti-Raf-1 antibody (Santa Cruz Biotechnology) was
added for incubation at 4°C for 2 hr with rotation. A total of 10 l
of a 50% slurry of protein A-sepharose 4B beads (Zymed) was
added for further incubation at 4°C for 1 hr with rotation. The beads
were pelleted by centrifugation at 10,000 × g for 5 s. The superna-
tant was carefully removed and subjected to SDS-PAGE, followed
by Western blot analysis with mouse anti-RKIP antibody (Zymed)
and chemiluminescent detection with goat anti-mouse IgG conju-
gated to horseradish peroxidase (Santa Cruz Biotechnology).
ALDH1A1 Enzyme Assay
ALDH1A1 purified from cultured A549 cells, in which it is highly
expressed, was added to a final concentration of w67 nM to the
assay mixture (100 mM Tris-HCl [pH 8.0], 100 mM KCl, 11 mM
β-mercaptoethanol, 6.7 mM NAD+, 3.3 mM acetaldehyde). Absor-
bance at 340 nm was measured at 1 min intervals for 30 min at
25°C. Reaction progress curves were linear in the initial phase in
this and the subsequent enzyme assays, and these were used to
calculate the rates of the enzyme reactions in all cases.
POP Enzyme Assay
The fluorogenic substrate Z-Gly-Pro-aminomethylcoumarin was
used as POP substrate in the assay buffer (20 mM Tris-HCl [pH
7.3], 1 mM EDTA, 1 mM DTT). The release of fluorescent AMC upon
addition of POP at 25°C was monitored by using excitation and
emission wavelengths of 381 nm and 455 nm, respectively, at 30 s
intervals for 10 min on an Flx800 microplate fluorescence reader
from Bio-Tek Instruments.
GSTO1-1 Enzyme Assay
The DHA reductase and thiol transferase activities of GSTO1-1
were assayed. DHA reductase activity was assayed in 100 mM Tris-
HCl (pH 8.0), 1 mM reduced glutathione, 0.25 mM DHA, to which
GSTO1-1 was added to a final concentration of 1 M. Starting
10 s after the addition of GSTO1-1, absorbance at 265 nm was
measured at 5 s intervals for 10 min at 25°C. The thiol transferase
activity was assayed in 100 mM Tris-HCl (pH 8.0), 0.5 mM reduced
glutathione, 1 mM 2-hydroxyethyl disulfide, 0.4 mM NADPH, 1 U
glutathione reductase. Beginning 10 s after the addition of GSTO1-1
to 1 M, absorbance at 340 nm, which decreases with oxidation of
NADPH, was measured at 30 s intervals for 10 min at 25°C.
Kinetics of Association of Locostatin with Proteins
The pseudo-first-order rate constant, kobs, was determined by plot-
ting the natural logarithm of the residual enzyme activity or the
fractional saturation as a function of time, then calculating the
slope of the line, which corresponds to −kobs. The second-order
rate constant (known as kassoc or kinact) for the inhibition of each
protein by locostatin was calculated by using the relationshipkassoc = kobs/[I], where [I] is the locostatin concentration. In this
way, the kassoc was determined for the inactivation of ALDH1A1,
GSTO1-1, and POP by locostatin. In all of these experiments,
R100× excess of locostatin over the concentration of each enzyme
was used to ensure pseudo-first-order conditions. The proteins
were incubated with locostatin at 25°C for different lengths of times
prior to dilution in the respective assay mixtures. Residual enzyme
activities were then measured. To determine the kinetics of alkyla-
tion of RKIP by locostatin, 1 M recombinant RKIP was incubated
with 100 M locostatin (a mixture of 20 M [3H]locostatin and 80
M unlabeled locostatin) for different lengths of time at 25°C in 50
mM Na2PO4 (pH 8.0), 2 mM EDTA, 2 mM DTT, followed by SDS-
PAGE. The gel was stained with Coomassie blue, and the region of
the gel containing RKIP around 21 kDa was excised and dissolved
for scintillation counting. By 2 hr of incubation with [3H]locostatin
at 25°C, saturation binding of RKIP had been attained. We plotted
the natural logarithm of the fractional saturation of RKIP as a func-
tion of time (between 0 hr and 2 hr) to obtain kobs, and then calcu-
lated kassoc as described above.
Cloning, Silencing, and Overexpression of Canine
RKIP in MDCK Cells
We cloned the canine RKIP gene, amplifying it from MDCK cell
cDNAs by the polymerase chain reaction with Pfu DNA polymerase
by using primers 5#-CCGCTCGAGCGGCTATGCCGGTGGACCTCG
GCAAG-3# and 5#-GCTCTAGAGCACTGCCCTACTTCCCAGACAGC-3#.
Subsequent DNA sequencing confirmed identity with the predicted
gene from dog genomic sequence (GenBank accession number
XM 534698).
We constructed an RNA polymerase II-directed siRNA expres-
sion vector from the pTRE2hyg vector for use in the Tet-Off in-
ducible system (BD Biosciences Clontech), guided by previous
publications [43–45]. The EGFP expression cassette from the
pEGFP-C1 mammalian expression vector was inserted between
the ApaI and BglII restriction sites of pTRE2hyg at nucleotide posi-
tions 1086 and 1255, respectively. A new BamHI site was intro-
duced immediately after position 371 of the modified pTRE2hyg.
We synthesized an optimized SV40 poly-A signal sequence, based
on the poly-A signal sequence of the Ambion pSilencer 4.1-CMV
RNA polymerase II-directed siRNA expression vectors, that in-
cluded an SpeI site at the upstream end and a NotI site at the
downstream end. This poly-A signal sequence was then introduced
immediately upstream of the NotI site in the multiple cloning site of
the modified vector.
Five different siRNAs were constructed as short hairpin RNAs
(shRNAs, also known as hairpin siRNAs) corresponding to different
target sequences in the canine RKIP gene, and each was inserted
between the new BamHI and SpeI sites, just upstream of the new
poly-A signal sequence. Expressed shRNAs are processed in the
cell to siRNAs that silence or knock down expression of their tar-
gets (for review, see [46]). The structures of our cloned constructs
were confirmed by DNA sequencing. Each construct was then
transfected into Tet-Off MDCK cells (BD Biosciences Clontech) by
using lipofectamine, according to the manufacturer’s protocol (Invi-
trogen). Stable transfectants were selected and maintained in 400
g/ml hygromycin B and 1 g/ml doxycycline in MEM with 10%
NCS, and EGFP-expressing cells were collected. Induction of each
shRNA/siRNA was accomplished by withdrawing doxycycline from
the medium. Knockdown was confirmed by Western blot analysis
by using the same anti-RKIP antibody as described above and then
mouse anti-β-actin antibody (Santa Cruz Biotechnology) as loading
control. An shRNA/siRNA corresponding to nucleotides 285–303 of
the canine RKIP gene was particularly effective at silencing RKIP
expression and was therefore used for wound closure experiments.
The control was an inert shRNA/siRNA in the same vector that did
not affect expression of RKIP. After 4 days in the absence of doxy-
cycline, cell monolayers were scratch wounded and then analyzed,
as described earlier. While we found RKIP knockdown even in the
presence of doxycycline, indicating “leakiness” of the modified Tet-
Off system, this was not a problem since the cells displayed no
obvious changes in growth rate or morphology despite silencing of
RKIP expression.
For overexpression of RKIP, the canine RKIP gene was fused to
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990enhanced green fluorescent protein (EGFP) by ligation into the XhoI
and XbaI restriction sites of the pEGFP-C1 mammalian expression
vector, which drives insert fusion gene expression from the CMV
immediate early promoter. After propagation in E. coli, the EGFP-
RKIP construct was purified and sequenced to confirm its proper
identity. The construct was then transfected into MDCK cells by
using lipofectamine, as described above. Stable transfectants were
selected and maintained in 500 g/ml G418 sulfate in MEM with
10% NCS. Stable transfectants with empty pEGFP-C1 vector were
also prepared as control cells.
Supplemental Data
Supplemental Data including Supplemental Experimental Pro-
cedures and two tables are available at http://www.chembiol.com/
cgi/content/full/12/9/981/DC1/.
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